Betaserc tablets 24mg, No. 20

• Meniere's disease;

• syndromes characterized by dizziness, tinnitus and / or progressive hearing loss, incl. dropsy of the labyrinth of the inner ear, vestibular and labyrinthine disorders (including dizziness, noise and ear pain, headache, nausea, vomiting, hearing loss), vestibular neuritis, labyrinthitis, benign positional vertigo (including after neurosurgical operations);

• vertebrobasilar insufficiency,

• post-traumatic encephalopathy,

• cerebral atherosclerosis (as part of complex therapy).

The drug is taken orally with meals.

The dose should be selected individually depending on the response to treatment.

For adults, the dose is 48 mg / day. Betaserc 24 mg should be taken 1 tab. 2 times / day

The tablet can be divided into 2 equal parts.

To do this, place the tablet on a hard surface with the line up and press down on it with your thumb.

Improvement is sometimes observed only after a few weeks of treatment, and a stable therapeutic effect after several months of treatment.

There is evidence that administration of the drug early in the disease prevents its progression and / or hearing loss in later stages.

Despite the limited data from clinical trials, extensive post-marketing experience suggests that dose adjustment in elderly patients is not required.

Special clinical studies in patients with renal and / or hepatic insufficiency have not been carried out, however, post-registration experience suggests that dose adjustment in this group of patients is not required.

White or off-white tablets

Active substance:

betahistine dihydrochloride

• Hypersensitivity to betahistine,

• pheochromocytoma,

• peptic ulcer of the stomach and duodenum in the acute phase,

• bronchial asthma,

• I trimester of pregnancy.

With care: II and III trimesters of pregnancy, breastfeeding period; childhood.

pharmachologic effect

Synthetic analogue of histamine. Acts like histamine, mainly on histamine H1 receptors. Causes expansion of precapillaries, in particular, facilitates microcirculation in the labyrinth. In addition, betahistine regulates endolymph pressure in the labyrinth and cochlea, leading to clinical improvement in vertigo of various etiologies. Reduces the frequency and intensity of dizziness, reduces tinnitus, improves hearing in cases of hearing loss. Increases the tone of the smooth muscles of the bronchi, gastrointestinal tract. May cause increased gastric acid secretion.

Pharmacokinetics

After oral administration of betahistine, dihydrochloride is rapidly and almost completely absorbed from the gastrointestinal tract. Plasma protein binding is low. Almost completely excreted from the body with urine within 24 hours. T1 / 2 - 3-4 hours. Side effect From the digestive system: slight nausea, a feeling of heaviness in the epigastrium are possible. Allergic reactions: in some cases - skin rash, itching, urticaria.

Application during pregnancy and lactation

Use is contraindicated in the first trimester of pregnancy.

It should be used with caution in the II and III trimesters of pregnancy. Use during breastfeeding is not recommended.

Application in children

Use with caution in children.

special instructions

It should be used with caution in patients with a history of gastric ulcer or duodenal ulcer, in the II and III trimesters of pregnancy, as well as in children. It should be borne in mind that the desired clinical effect is achieved after several months of treatment. For dyspeptic symptoms, betahistine is recommended to be taken during or after meals.

Drug interactions

Antihistamines, when taken simultaneously, reduce the effect of betahistine.